CAR-T Cell Therapy: Current Status and Future Directions

Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a revolutionary advancement in cancer treatment, particularly for hematologic malignancies. CAR-T cell therapy involves engineering a patient’s T cells to express a receptor that specifically targets cancer cells, enhancing the body's ability to combat the disease. Numerous clinical trials are ongoing to evaluate the safety and efficacy of CAR-T cell therapy in other types of cancers, including solid tumors. Trials are also exploring combinations of CAR-T therapy with other treatments, such as checkpoint inhibitors, to enhance therapeutic outcomes. Cytokine release syndrome (CRS) and neurotoxicity are significant adverse effects associated with CAR-T cell therapy. Managing these toxicities is critical for patient safety.

    Related Conference of CAR-T Cell Therapy: Current Status and Future Directions

    October 14-15, 2024

    17th World Congress on Stem Cell Research

    Paris, France
    November 21-22, 2024

    11th World Congress on Epigenetics and Chromosome

    Dubai, UAE
    March 17-18, 2025

    8th Global Conference on Cell and Gene Therapy

    Paris, France
    June 16-17, 2025

    21st Global Summit on Stem Cell & Regenerative Medicine

    Frankfurt, Germany

    CAR-T Cell Therapy: Current Status and Future Directions Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in